title: Comparison of two forms of continuous combined hormone replacement therapy with respect to metabolic effects.
abstract: OBJECTIVE
  To compare the metabolic effects of two frequently used continuous hormone replacement therapies.
  
  
  METHODS
  Two hundred and forty-six menopausal women, aged between 41 and 57 years were enrolled in the present study. They were randomized to receive either estrogen + 2.5 mg medroxyprogesterone acetate (CEE/MPA) or 1 mg 17 <beta> estradiol + 0.5 mg norethindrone acetate (E2/NETA). Women in group I (n = 139) and group II (n = 107) were followed up for 1 year and compared with respect to total cholesterol, triglycerides, HDL, LDL, VLDL, weight gain during this period.
  
  
  RESULTS
  The basal and 12th month weight of the patients of two groups were not statistically different (P = 0.57 and P = 0.17, respectively, in the groups I and II). No changes were detected in the levels of triglycerides, HDL and VLDL, while total cholesterol (P = 0.01) and LDL (P = 0.003) levels significantly decreased in the CEE/MPA group. In group 2, total cholesterol and triglyceride levels showed no significant change, however, levels of HDL cholesterol (P = 0.001) increased and LDL (P = 0.001) and VLDL cholesterol (P = 0.006) decreased significantly.
  
  
  CONCLUSIONS
  Administration of E2/NETA regimen has better results on lipid profile when compared to CEE/MPA regimen. No weight gain is recorded in E2/NETA group.
authors.affiliation: Zeynep Kamil Women and Children's Education and Research Hospital, Istanbul, Turkey. astugrul@superonline.com
authors.forename: Semih
authors.initials: S
authors.lastname: Tugrul
authors.forename: Gazi
authors.initials: G
authors.lastname: Yildirim
authors.forename: Oya
authors.initials: O
authors.lastname: Pekin
authors.forename: Hüsamettin
authors.initials: H
authors.lastname: Uslu
authors.forename: Tayfun
authors.initials: T
authors.lastname: Kutlu
authors.forename: Sadiye
authors.initials: S
authors.lastname: Eren
mesh_terms: D000328:Adult; D001835:Body Weight; D002784:Cholesterol / Q000097:blood*; D003271:Contraceptive Agents, Female / Q000627:therapeutic use; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004967:Estrogens / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D008593:Menopause; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: D003271:Contraceptive Agents, Female; D004967:Estrogens; D008074:Lipoproteins; D014280:Triglycerides; D004958:Estradiol; D002784:Cholesterol; D000077563:Norethindrone Acetate; D017258:Medroxyprogesterone Acetate; D009640:Norethindrone